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ABSTRACT
Introduction Pancreatic cancer is characterised by
severe mid-back and epigastric pain caused by tumour
invasion of the coeliac nerve plexus. This pain is often
poorly managed with standard treatments. This clinical
trial investigates a novel approach in which high-dose
radiation (radiosurgery) is targeted to the retroperitoneal
coeliac plexus nerve bundle. Preliminary results from a
single institution pilot trial are promising: pain relief is
substantial and side effects minimal. The goals of this
study are to validate these findings in an international
multisetting, and investigate the impact on quality of
life and functional status among patients with terminal
cancer.
Methods and analysis A single-arm prospective phase II
clinical trial. Eligible patients are required to have severe
coeliac pain of at least five on the 11-point BPI average
pain scale and Eastern Cooperative Oncology Group
performance status of two or better. Non-pancreatic
cancers invading the coeliac plexus are also eligible. The
intervention involves irradiating the coeliac plexus using
a single fraction of 25 Gy. The primary endpoint is the
complete or partial pain response at 3 weeks. Secondary
endpoints include pain at 6 weeks, analgesic use,
hope, qualitative of life, caregiver burden and functional
outcomes, all measured using validated instruments. The
protocol is expected to open at a number of cancer centres
across the globe, and a quality assurance programme is
included. The protocol requires that 90 evaluable patients"
be accrued, based upon the assumption that a third of
patients are non-evaluable (e.g. due to death prior to
3-weeks post-treatment assessment, or spontaneous
improvement of pain pre-treatment), it is estimated that
a total of 120 patients will need to be accrued. Supported
by Gateway for Cancer Research and the Israel Cancer
Association.
Ethics and dissemination Ethic approval for this study
has been obtained at eight academic medical centres
located across the Middle East, North America and
Europe. Results will be disseminated through conference
presentations and peer-reviewed publications.
Trial registration number NCT03323489.

Strengths and limitations of this study
► The trial focuses on an urgent unmet clinical need:

►

►

►

►

patients with advanced cancer whose pain is refractory to narcotic analgesics.
The technique being tested is non-invasive, and can
be easily implemented using contemporary, widely
available radiotherapy equipment. Results from the
pilot study are promising.
The trial will provide a broad insight into the functional and social aspects of pain’s impact on patients' lives through the use of a range of validated
instruments assessing quality of life, functional outcomes, hope and caregiver burden. Moreover, the
trial will investigate whether the intervention is able
to reverse these changes.
The primary limitation of the study is the use of pain
as both an eligibility criterion and the primary endpoint. Pain is a complex subjective experience that
is difficult to measure, and somewhat unstable. The
concurrent use of opioid analgesics will complicate
the efficacy assessment.
The non-randomised design is a limitation.

INTRODUCTION
Coeliac pain in pancreatic and other
malignancies
Pain is a characteristic feature of pancreatic
cancer, both at diagnosis1 2 and in terminal
disease.3 Pain is more frequently seen in
tumours of the body and tail, than the head
of pancreas.4 Almost one-
third of patients
define the pain as being of at least moderate
to severe intensity at diagnosis,1 and one-third
of subjects report poor pain relief despite oral
analgesics.1 The pain is associated with a poor
quality of life and depression.1 5 6 Pancreatic
cancer is common, with over 50 000 cases
annually in each of the USA7 and Europe,8
moreover, incidence appears to be rising.9
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Pancreatic cancer pain typically emanates from the
mid-back and radiates to the epigastric area, termed the
midline retroperitoneal pain syndrome.10 Tumour invasion of the coeliac nerve plexus is thought to be the cause
the pain.11 Other tumour types metastatic to the retroperitoneum/coeliac axis region may induce a similar pain
syndrome.
Current palliative approaches for the retroperitoneal
pain syndrome include the use of analgesics, coeliac
nerve block and systemic chemotherapy. Opioid analgesics (ie, morphine, oxycodone, fentanyl) are commonly
used in pancreatic cancer,12 yet the high doses frequently
required are associated with side effects including constipation, sedation, pruritus and nausea.11 These side effects
may prevent patients from obtaining adequate pain relief.
For refractory coeliac pain, invasive procedures may
be considered, especially ‘coeliac plexus neurolysis’ and
‘coeliac plexus block’, performed either via a transcutaneous or transoesophageal approach. The chemical
ablation or numbing of nerve fibres transmitting signals
from the intra-abdominal viscera to higher nerve levels,
aims to alleviate pain. Some trials have shown significant
pain reduction and lower opioid consumption following
the procedure,13–17 but other data did not suggest an
improved quality of life,18 furthermore, the degree of
pain relief appears to be modest. A recent randomised
trial of endoscopic coeliac plexus neurolysis failed to
demonstrate a reduction in pain compared with analgesics alone.17 19
Systemic chemotherapy is another option. Both gemcitabine20 and combination treatment with oxaliplatin, irinotecan, fluorouracil and leucovorin21 have been shown
to reduce pain and improve quality of life in pancreatic
cancer, however, these treatments are associated with side
effects, and the analgesic benefit is often short-lived.
Hence pain remains a substantial problem for many
patients with pancreatic cancer and other malignancies
of the upper abdomen involving the coeliac plexus. The
pancreatic cancer pain syndrome has been identified by
Prof Nathan Cherny for the European Society for Medical
Oncology as a uniquely ‘difficult pain problem’.10 Progress has been limited, as reflected by a population-based
study from Australia published in 2016, that identified
‘pain’ as a frequently unmet need among people with
pancreatic cancer.22
GROSS AND NEUROANATOMY OF THE COELIAC PLEXUS
The coeliac plexus is a dense network of interconnecting
nerve fibres connecting the coeliac, superior mesenteric and renal ganglia. Anatomically it extends over the
anterolateral surface of the aorta, around the origins
of the coeliac and superior mesenteric arteries.16 The
coeliac plexus demonstrates considerable variability in
size and position. Nonetheless 94% of the coeliac ganglia
are located at the level of T12 or L1 vertebrae.
The coeliac plexus is composed of both efferent and
afferent, sympathetic and parasympathetic nerve fibres.
2

Of key importance to this protocol, the visceral afferent
fibres that carry nociceptive stimuli from the upper
abdominal viscera (including the pancreas, liver, biliary
tract, gallbladder and the small bowel) pass through the
coeliac plexus before terminating in the dorsal horn of
the thoracic cord. Hence the coeliac plexus represents
the main target point of pain transmission from the
upper abdominal organs.
CONTEMPORARY USE OF RADIATION FOR PALLIATION IN
PANCREATIC CANCER
The contemporary use of radiation as a palliative modality
in pancreatic cancer is limited. Several small retrospective
studies23–26 using various radiation doses, have suggested
that radiotherapy is a safe and effective palliative modality
in pancreatic cancer; however, the studies size and retrospective nature, limit the generalisable of their findings.
One retrospective analysis recommended a dose of 30 Gy
in 10 fractions.25
PILOT STUDY
A small pilot study performed at the Sheba Medical
Center between 2013 and 2017 examined the palliative
role of coeliac plexus radiosurgery (
ClinicalTrials.
gov
NCT02356406). The radiation dose was originally 45 Gy
in five fractions, but later amended to a single fraction of
25 Gy.27 The primary endpoint was pain relief 3 weeks’
post-treatment. Twenty-five subjects underwent treatment
with a single fraction, of whom 18 were evaluable. Median
age of 68 years, median Eastern Cooperative Oncology
Group (ECOG) 1, 89% had pancreatic cancer. The
pain relief following intervention was substantial, with
minimal side effects. The manuscript with full results was
submitted for publication.
KEY HYPOTHESES
► Ablative radiation targeted to the coeliac plexus will
alleviate pain.
► Decreased pain will be associated with improved
patient functionality, quality of life and hope.
► Decreased pain will be associated with decreased
caregiver burden.
Patients with pancreatic cancer suffer from impaired
functioning and quality of life. We hypothesise coeliac
plexus tumour infiltration to be the fundamental cause of
pain, and consequent decreased functionality, decreased
quality of life, increased opioid usage, impaired hope
and resultant caregiver burden. By intervening at an
early stage in the pathway, that is, blocking of coeliac
plexus induced pain, we hypothesise that we will be able
to reverse these negative processes, reducing suffering
and consequently improve patients' hope and potentially their ability to undergo further treatments. Figure 1
shows a model of how radiosurgical intervention impacts
patient well-being. Conversely, we acknowledge that some
Jacobson G, et al. BMJ Open 2022;12:e050169. doi:10.1136/bmjopen-2021-050169
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Figure 1

Model of how radiosurgical intervention is hypothesised to impacts patient well-being. QOL, quality of life.

pain and suffering is unrelated to the coeliac plexus, for
example, pain resultant from liver metastases and peripheral neuropathy resultant from cytotoxic chemotherapy.
These symptoms are not expected to be improved by our
intervention (coeliac plexus radiotherapy) and hence are
identified in our model as competing causes of suffering.
METHODS AND ANALYSIS
This protocol described a multicentre, single-arm phase
II interventional trial, assessing a new radiation technique
for pain management. Patients will be recruited in the
oncology departments of participating hospitals.
ELIGIBILITY CRITERIA
Key inclusion criteria
► Age ≥18 years.
► A malignancy that is metastatic or unresectable.
► Severe retroperitoneal pain syndrome (radiates from
the lower back to the upper abdomen, belt-like distribution), intensity of at least 5 on 11 point Brief Pain
Inventory (BPI, average pain) scale despite analgesic
use.
► Anatomical involvement of the coeliac plexus, as
defined by either:
– Any Pancreatic cancer.
– Any other cancer that on imaging demonstrates either: gross involvement of the coeliac blood vessels
or coeliac plexus on imaging OR haziness around
the coeliac blood vessels, that typically implies tumour engulfment.
► Prior chemotherapy or biological treatment is allowed,
but any active oncological treatment should be
stopped at least 6 days prior to radiation therapy and
renewed at least 6 days following radiation therapy.
Jacobson G, et al. BMJ Open 2022;12:e050169. doi:10.1136/bmjopen-2021-050169

Key exclusion criteria
Patients who are well balanced in terms of pain
control.
► Patients with life expectancy <8 weeks.
► Significant comorbidities.
► Patients with ECOG Performance status 3 or 4.
► Previous radiotherapy to upper abdomen.
► Conditions associated with increased side effects
to radiotherapy (eg, inflammatory bowel disease,
scleroderma).
Of note, previous use of a coeliac plexus block/neurolysis (or similar procedure) is allowed and does not interfere with the trial, but will be recorded.
►

INTERVENTION
Figure 2 shows a schema of the study recruitment process
and overall study design. Patients should be simulated
supine with arms above the head on a chest board, with
oral and intravenous contrast administered. The three-
dimensional simulation CT scan should span from the
carina until at least L5-S1 with a slice thickness, 3 mm or
less. A motion management technique (eg, 4 Dimensional
- Planning Organ at Risk Volume, 4D-PRV) approach,
breath-hold or gating) is required.
CONTOURING
The coeliac plexus is not visible on conventional imaging.
The anterior and medial aspects of the aorta from the
levels of the T12–L2 vertebrae inclusive are contoured as
a surrogate structure (figure 3). The inclusion of tumour
immediately adjacent to the coeliac plexus, and the
prescribed dose to such tumour, is left to the physician’s
discretion but will be recorded. The following normal
structures need to be contoured: spinal cord, liver,
3
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Accrue
Cancer involvement of celiac nodes / plexus
Lower back/abdominal pain ≥ 5/10 on BPI average pain scale
Age >=18 years
Exclude: prognosis < 8 weeks, poor performance status

Informed
consent

Radiation
planning

Radiation
treatment

Aim 10 days. Max 4 weeks.

Brief
Pain QOL
assessment
At consent

Detailed
Pain QOL
assessment
Pre-treatment

Intensive Follow up

Long term safety
Follow up

6 weeks

Until death

Detailed
Pain QOL
assessment
Week #3

Detailed
Pain QOL
assessment
Week #6

Figure 2 Trial schema. QOL, quality of life.
Q0L: Quality Of Life

kidneys, stomach-duodenum and small bowel in accordance with Radiation Therapy Oncology Group, RTOG
guidelines.23 The duodenum is the critical structure
of especial concern due to its proximity to the coeliac
plexus. The stomach, small bowel, large bowel and sometimes the oesophagus must also be considered.
DOSE PRESCRIPTION AND CONSTRAINTS
The prescription dose to the coeliac plexus is 25 Gy. The
duodenum lies in close proximity to the coeliac plexus,

yet is very sensitive to radiation. To overcome this challenge a dose-painting technique was developed; briefly,
bowel loops are to be precisely contoured. Within the
coeliac plexus contour, voxels within 0.5 cm of bowel will
be prescribed 10 Gy (modPTV 10), those at least 0.5 cm,
but no more than 1 cm from the bowel, will be prescribed
15 Gy (modPTV 15). Voxels at least 1 cm from the bowel
within the coeliac plexus itself will be prescribed 25 Gy
(modPTV 25), and those within the 0.5 cm isotropic
expansion of the coeliac plexus 20 Gy (modPTV 20).

Figure 3 Coeliac plexus target deliniation anterior and medial aspects of the aorta contoured from top of T12 to bottom of L2,
a surrogate structure for the coeliac plexus (yellow structure).
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Table 1 Acceptable and unacceptable variations in D2% and D95% of each PTV
Name of
structure

D2%
Typical
acceptable
mean dose D2% aim deviation

modPTV25
modPTV20

25.5±2
22±2

modPTV15
modPTV10

17±1.5
12±1

26
24.5

D2%
unacceptable
deviation

≤2 Gy more/less ≥2 Gy more/less
than ‘D2% aim’ than ‘D2% aim’

20
14

95%
acceptable
D95% aim deviation

D95%
unacceptable
deviation

24
19

≥2 Gy more/less
than ‘D95% aim’

14
10

≤2 Gy more/
less than
‘D95% aim’

PTV, Planning Target Volume.

Acceptable and unacceptable variations in D2% and
D95% of each PTV are detailed in table 1.
Dose constraint’s for normal organs are provided in
table 2. In general, the ‘organs at risk’ dose limits have a
higher priority than the target structure modPTVs. When
calculating maximum dose, very small volumes <0.3 cc
(ie, the hot but very thin tail of the Dose-Volume Histogram, DVH) may be ignored.
TREATMENT DELIVERY
Treatment will be delivered with a megavoltage LINAC,
preferably within ten days of simulation. It is essential that
image-guided radiation therapy techniques be employed.
As a minimum, a cone-beam CT should be performed
in the treatment position prior to treatment. It is recommended to give oral contrast or water 20 min prior to
treatment in order to visualise the duodenum better. The
conebeam CT should be matched on the small bowel/
aorta.
PROPHYLACTIC ANTIEMETIC TREATMENT
All patients are recommended to received prophylactic
antiemetic medication, such as a single dose of combined
netupitant/palonosetron, 8 mg dexamethasone and
a proton pump inhibitor (mandatory, continue for 4
weeks). As an alternative netupitant/palonosetron may
be replaced with ondansetron 8 mg two times per day for
2 days.
CONCOMITANT MEDICATIONS
Anticancer treatments including chemotherapy, targeted
anticancer agents, and immunotherapy should be not be
administered at least 6 days prior to and 6 days following

treatment. All other medications may be continued
during the treatment.

PAIN MEDICATIONS
No limitations are placed on the use of pain medications
before or after treatment. The majority of subjects on
this protocol will be receiving substantial doses of opioid
medications, both long acting and short acting. The use,
type and dosage of opioids will be carefully recorded
and converted into intravenous morphine milligram
equivalents.
A palliative nurse is the responsible for maintaining
weekly contact with patients, assessing pain levels and
modifying opioid use as appropriate. These contacts
should preferably commence prior to receiving radiation
therapy. Patient should be educated to take breakthrough
medication only as needed for pain, not on a regular
basis, and to advise the team if pain levels decrease so that
long-term opioid levels can be modified.

QUALITY ASSURANCE PROCEDURES
This trial incorporates several levels of quality assurance: (1) a benchmark case, requiring contouring and
treatment planning; (2) an online exam to ascertain
the subinvestigator’s understanding of the protocol; (3)
the initial three cases require pre-treatment authorisation by the principal investigator, and other cases
at the investigators discretion and (4) post-treatment
quality assurance at the conclusion of the trial. Furthermore, within each institution, peer-
to-
peer review is
recommended.

Table 2 Dose constraints for normal organs
Recommended

Acceptable deviation

Each kidney

Mean dose ≤5.5 Gy.

Bowel

Less than 1 cc receive 11 Gy.

One individual kidney has a mean dose of <7.5 Gy, but both functional
kidneys together have a mean dose of ≤5.5 Gy.
No more than 5 cc receive over 12 Gy. Max 15 Gy.

Liver
Spinal cord

700 cc receive less than 10 Gy.
Max. dose 10 Gy

 
Less than 1 cc receive 11 cc.

Jacobson G, et al. BMJ Open 2022;12:e050169. doi:10.1136/bmjopen-2021-050169
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Table 3 Validated instruments to assess patients' pain level, quality of life, functional status, hope level and caregiver burden
Instrument

Comments

Pain intensity

Brief Pain Inventory Short
form (BPI-SF)

Developed by Cleeland for measuring pain related to cancer, the BPI-SF incorporates
an 11 point (0–10) numerical rating scale for pain. A two-point decrease on the 0 to 11
pain intensity numerical rating scale is considered equivalent to a 30% change in pain
intensity,36 and represents 'notable improvement'. The BPI-SF also includes measures
of pain interference with daily function.34

Quality of life

FACT-Hep

A 45-item self-report instrument was developed specifically to measure HRQoL
in patients with hepatobiliary cancer.3 4 6 It consists of the backbone FACT-G
questionnaire, which assesses symptoms and other HRQoL concerns across four
dimensions (physical well-being (seven items), social/family well-being (seven items),
emotional well-being (six items)and functional well-being (seven items)) together with
an 18-item disease-specific hepatobiliary cancer subscale (HCS). The HCS assesses
back and stomach pain, gastrointestinal symptoms, anorexia, weight loss and
jaundice in patients with hepatobiliary cancers.

Side effects/toxicity

Common Terminology Criteria A standardised system to quantify or grade the severity of adverse events that occur
for Adverse Events V.4.03
with drug treatment or from medical devices, developed by the CTEP of the NCI37

Hope

The Goal Assessment Scale

The ‘Goal Assessment Scale’ contains six items. Three items measure pathways
thinking, and three items measure agency thinking. Participants respond to each item
using an 8-point scale ranging from definitely false to definitely true and the scale
takes only a few minutes to complete.10

Functional assessment

6 min walk test.
Handgrip strength test.

These test how far the patient can walk in 6 min, and their maximal hand-grip
strength. Both tests have been validated in patients with cancer.11 12 Standardised
methods will be used.

Caregiver burden

Short version of the Zarit
Burden Interview.

Caregiver burden is commonly used to describe the multiple dimensions of distress
that result from an imbalance between care demands and the availability of resources
to meet those demands.13 We will use a validated shortened 12 item version of the
original interview.14 15

Activity

Measured by wearable fitness This will be measured by an electronic wearable device, for example, manufactured
tracker.
by Garmin (Olathe, Kansas) or Fitbit (San Francisco, California), from the time of
registration until the 6 weeks follow-up visit. Of note, this is an optional experimental
endpoint that both institutions and individuals can decide to opt out of.

The caregiver burden questionnaire is completed by an accompanying caregiver.
CTEP, Cancer Therapy Evaluation Program; FACT-G, Functional Assessment of Cancer Therapy - General; HRQoL, Health Related Quality of Life;
NCI, National Cancer Institute.

PATIENT REPORTED OUTCOMES/ HEALTH-RELATED QUALITY OF
LIFE INSTRUMENTS TO BE USED
A range of validated instruments will be used to assess
patients' pain level, quality of life, functional status, hope
level and caregiver burden (table 3). An additional experimental instrument that will be offered to participants is
use of a fitness tracker (also called an activity tracker).
The device will record daily step count and sleep hours
on a daily basis.
BIOSTATISTICAL CONSIDERATIONS
Definition of evaluable patient
An evaluable patient is defined as a patient, eligible for
enrolment per the defined criteria, who has received
the therapy per protocol and remains alive until the
3-week post-treatment pain and quality of life assessment.
A further evaluability criterion is that BPI average pain
remains greater than or equal to 4 on the 11-point scale
at the assessment immediately before the first treatment
(the eligibility level cut-off at recruitment is 5). This is
required to ensure that all patients have pre-treatment
pain at a sufficient level to allow detection of pain relief
following treatment. An additional criterion is that any
6

reduction between the screening BPI and the BPI immediately before the treatment is no more than two. Toxicity
will be assessed in all patients, even those who do not
complete the 3-week post-treatment assessment.
SAMPLE SIZE
The authors consider the radiosurgical procedure to be
justified if at least 40% will have a successful outcome.
Assuming that the true response rate is 60%, a trial with
100 patients will have a 97% chance of demonstrating at
a one-sided statistical significance level of 2.5% that the
response rate is at least 40%. This calculation assumes
and takes into account that 10% of patients will be non-
evaluable. Therefore, during the trial, the number of
evaluable patients will be monitored, and a minimum
of 90 evaluable patients will be entered. A principal aim
of the study is to estimate the pain response rate. With
a 60% success rate and 100 patients entered, the SE of
the estimated response rate will be ~5%, and the 95% CI
will be approximately ±10% around the point estimate. It
was noted mid-trial that approximately a third of patients
were non-
evaluable, hence a larger number (approx.
120) would be needed to achieve 90 evaluable patients.
Jacobson G, et al. BMJ Open 2022;12:e050169. doi:10.1136/bmjopen-2021-050169
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ENDPOINTS
The primary endpoint is complete or partial pain response,
based on the BPI average pain 11-point scale, defined as
a decrease between the score immediately before treatment and 3 weeks’ post-treatment, that is, two or more,
and is also at least two more than any decrease between
registration and the score immediately before treatment.
Some patients find it difficult to verbally express their
pain from 'zero to ten' (Numeric Rating Scale, NRS), for
such patients it may be useful to use the following Visual
Analogue Scale (VAS). Most studies have found the NRS
to correlate well with the VAS,28–30 however, it is best to be
consistent in their use for each individual patient.31
Secondary endpoints include changes from baseline to
both 3-week and 6-week post-treatment in the following
metrics: ‘BPI average pain’, ‘BPI worse pain’, ‘daily opioid
usage’ (in mg intravenous morphine equivalent), overall
quality of life (FACT-Hep), Hepatobiliary Cancer QOL
subscale (a measure of gastrointestinal toxicity), functionality (handgrip, walking, daily step count), use of short-
acting opioids for breakthrough pain measured both in
morphine-equivalent dose per day and times taken per
day.
Exploratory endpoints include a change in caregiver
burden (Zarit Burden Interview, short 12-item version),
change in Goal Assessment Scale, and change in the
number of times short-acting opioids were used for breakthrough pain (‘rescue analgesic doses’), averaged over
the previous 3 days, sleep as assessed with an activity
tracker. Interactions between pain dynamics, the intervention and analgesic use will be assessed both graphically and analytically—using for instance the integrated
method used by Mercadant17
STATISTICAL ANALYSIS
The response rate will be estimated as the proportion of
evaluable patients who achieve a complete or partial pain
response. The 95% CIs will be calculated based on the
binomial distribution. A statistical test of the null hypothesis that the response rate is 40% (the rate that would
be considered large enough to justify the adoption of the
treatment assuming minimal toxicity) will be conducted
at the one-
sided 2.5% level, based on the binomial
distribution.
Patients who are still alive but do not provide a 3-week
pain assessment will be evaluable and will be included as
failures. However, a sensitivity analysis will be added in
which patients with no 3-week pain assessment will be
excluded. This alternative estimate of the response rate
and its CI, and the associated test of the null hypothesis
that the response rate is 40%, will be presented.
Two approaches will be taken to analyse the relationship
between changes in BPI average pain score and changes
in other endpoints: First, patients will be divided into two
subgroups: those with a defined pain response and those
with no response. Then for each of the other endpoints
the mean change in the endpoint at 3 weeks will be
Jacobson G, et al. BMJ Open 2022;12:e050169. doi:10.1136/bmjopen-2021-050169

computed for the two subgroups and compared using a
t-test. Second, the 3-week change in each endpoint will
be regressed on the change in the pain score at 3 weeks
and the linear slope and correlation coefficients will be
estimated. The test of the null hypothesis that there is
zero correlation will be tested using the t-test for a linear
association.
Exploratory analyses will be performed to identify
predictors of response (ie, understand who benefits most
from the intervention), and to test for heterogeneity of
response rate across centres. Furthermore, mediation
effects will be examined, for example, whether functionality is a mediator between pain and caregiver burden.
ETHICS AND DISSEMINATION
The study will be opened at a number of academic radiation
oncology departments worldwide. At the time of writing,
the study has been approved and opened at: Princess
Margaret Cancer Centre, Toronto, Canada; Mount Sinai
Hospital, New York, USA; Ohio State University Hospital,
Ohio, USA; Instituto Portugues de Oncologia, Porto,
Portugal; Assuta Medical Center, Tel Aviv, Israel; Sourasky
Medical Center, Tel Aviv, Israel; Maria Sklodowska-Curie
National Research Institute of Oncology, Gliwice, Poland.
Results will be disseminated through conference presentations and peer-reviewed publications.
INFORMED CONSENT
The patient will be approached and informed about the
trial by the investigator and provided with a copy of the
patient information and consent form. Patients will be
given an adequate amount of time to consider their participation in the trial and will be given an opportunity to ask
questions if needed. If the patient decides to participate
in the study, they will be asked to provide written consent.
All participants are free to withdraw from the study at any
time, without any prejudice to future medical treatment.
See online supplemental file 1 for the informed consent
form.
SAFETY
Adverse events will be recorded using NCI Common
Terminology Criteria for Adverse Events V.4.0 . Severe
adverse events will be reported urgently to both the
IRB and the principal investigator. At three prescribed
periods (after 10, 35 and 70 patients accrued), a data and
safety monitoring board (DSMB) will review the efficacy
and toxicity data. Long term follow-up for up to 2 years
will be performed to assess for efficacy and late toxicities.
PROTOCOL AMENDMENTS
Due to the COVID-19 pandemic that erupted in early
2020 the protocol was amended to allow follow-up visits
to be performed virtually (eg, over the telephone). The
7
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protocol initially adopted the Adult Hope Scale (AHS). In
September 2020, an amendment was made to the protocol
to use the ‘Goal Assessment Scale’ in place of the AHS.
This change was made since patients had great difficulty
completing the non-specific questions contained within
the AHS, some of which were felt to be inappropriate for
terminal patients, such as ‘I worry about my health’ and ‘I’ve
been pretty successful in life’. The ‘Goal Assessment Scale’
has been found to predict goal attainment better than the
AHS, which measures hope regarding goals in general.32
The current protocol is dated September 2020 V.1.5.
PATIENT AND PUBLIC INVOLVEMENT
During the single-institution pilot trial, patients expressed
satisfaction with both the treatment and trial design,
which have been closely replicated in the current multicentre trial. At patients’ request we encourage investigators to schedule follow-up visits on days when subjects are
already attending the hospital. Several patients expressed
interest in an electronic means of gathering pain scores
(eg, via smartphone)—and this has been implicated. A
detailed patient feedback form is incorporated into the
trial at 3-week and6-week post-treatment. Based on our
experience that patients are not always willing/able to
complete all questionnaires, a priority list has been incorporated into the protocol clarifying that pain and analgesic assessments have priority over functional and hope
assessments. Following consent, patients are incorporated
in media briefings aiming to boost accrual. Trial subjects
have limited life expectancies, hence direct dissemination to participants is inappropriate.
DISCUSSION
The purpose of this protocol is to establish a new treatment for refractory retroperitoneal cancer pain, characteristic of pancreatic neoplasms. Following on from a
promising pilot trial, the protocol will examine the treatment in a multicentre international meeting, establishing
both toxicity and efficacy data. Through use of extensive
secondary measures, we seek to understand the impact of
pain on these patients’ physical and psycho-social functioning, their caregivers and moreover what happens
after the pain improves.
The protocol has a number of limitations. First, the
primary endpoint is ‘pain level’ as measured on the
11-point BPI scale, likewise a ‘pain level’ of at least five
out of ten is an eligibility criteria. Pain is a subjective experience which cannot be objectively measured,30 33 being
influenced by many factors including stress, emotional
state1 and use of analgesics. The protocol uses the widely
accepted BPI instrument as a measure of pain,34 asking
patients to focus on the pain location described at baseline. An unexpected concern of the DSMB on reviewing
the ongoing trial’s data was the instability of pain. Patients
have pain recorded at least twice and sometimes three
times prior to treatment: at initial meeting with physician,
8

at signing of consent (often on a different day) and within
a week prior to treatment (often the day of treatment);
the DSMB noted that some patients had spontaneous
improvement of pain. The protocol was subsequently
amended to categorise such patients as ‘unevaluable’.
An additional obstacle is the challenging patient population: based on our pilot trial, we expect that many of
the enrolled subjects will have progressed on first-line
systemic treatment and hence have a limited life expectancy; in that trial median overall survival at accrual was
3 months. This poses a number of challenges—regarding
obtaining long-term follow-up data and the development
of multiple new palliative challenges that characterise
terminal cancer, including ascites, additional metastases
and depression. Hence even if the intervention is efficacious and the retroperitoneal pain improves, this may not
be reflected in improved quality of life, functional status
or mood.
Ideally, this would have been a randomised phase II
trial, possibly with a cross-over design, comparing coeliac
plexus radiosurgery with a standard of care—coeliac
nerve block or neurolysis. The investigators considered
the logistic challenges and expense of running such a trial
insurmountable; trials comparing different treatment
modalities are complex and frequently accrue poorly.35
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